|Mr. Michael W. Nall||Chief Exec. Officer, Pres and Director||526.25k||N/A||54|
|Dr. Lyle J. Arnold Ph.D.||Chief Scientific Officer, SVP of R&D and Member of Scientific Advisory Board||340.32k||N/A||70|
|Dr. Veena M. Singh M.D.||Sr. VP, Sr. Medical Director and Member of Scientific Advisory Board||361.03k||N/A||42|
|Dr. Soon Kap Hahn Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Timothy C. Kennedy||Chief Financial Officer, Sr. VP of Operations and Sec.||N/A||N/A||59|
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The companys cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Biocept, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.